PCRX Q2 2021 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$969M

Q2 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$136M+79.6% YoY

Gross Profit

$100M74.0% margin

Operating Income

$35M25.7% margin

Net Income

$19M14.1% margin

EPS (Diluted)

$0.42

QoQ Revenue Growth

+13.9%

Cash Flow

Operating Cash Flow

$30M

Free Cash Flow

$20M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$639M

Stockholders' Equity

$687M

Cash & Equivalents

$106M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$136M	$76M	+79.6%
Gross Profit	$100M	$53M	+88.6%
Operating Income	$35M	-$7M	+587.5%
Net Income	$19M	-$7M	+362.5%

Revenue Segments

Product

$135M99%

Royalty

$602,0000%

Collaborative Licensing and Milestone Revenue

$125,0000%